Roche Diagnostics GmbH
⚠️ High Risk
FEI: 3002806559 • Mannheim, Baden-Wurttemberg • GERMANY
FEI Number
3002806559
Location
Mannheim, Baden-Wurttemberg
Country
GERMANYAddress
Sandhofer Str. 116, , Mannheim, Baden-Wurttemberg, Germany
High Risk
FDA Import Risk Assessment
This firm has a significant history of FDA import refusals with notable violations.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
DIRECTIONS
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it is a device whose label appears to not bear adequate directions for use.
NO 510(K)
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it is a post 1976 device for which a Section 510(k)application does not appear to have been determined substantially equivalent or otherwise filed.
FRNMFGREG
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.
REGISTERED
It appears the device is subject to listing under 510(j) and the initial distributor has not registered as required by 21 CFR 807.20 (a)(5).
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
DRUG NAME
The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient.
NO LICENSE
The article is subject to refusal of admission under section 801(a)(3) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because it appears to be a biological product for which a biologics license is not in effect under the Public Health Service Act, Part F, Subpart 1-Biological Products, Section 351(a), and it is not the subject of an Investigational New Drug application that is in effect. Therefore, it appears to be a new drug under 201(p) of the FD&C Act that it is in violation of section 505(a) of the FD&C Act because it lacks a new drug approval and because it is misbranded under section 502(f)(1)of the FD&C Act because it fails to bear adequate directions for use
LACKS FIRM
The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.
NO ENGLISH
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(f) of the FD&C Act in that any word, statement, or other information required by or under the authority of the FD&C Act to appear on the label or labeling is not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary terms of purchase and use (for example, label contains information in two or more languages but fails to repeat all required information in both languages in accordance with 21 CFR 101.15(c)(2), or label fails to include all required information in English in accordance with 21 CFR 101.15(c)(1), except in the case of articles distributed solely in the Commonwealth of Puerto Rico or in a Territory where the predominant language is one other than English)).
DEVICEGMPS
The article is subject to refusal of admission pursuant to Section 801(a)(1) in that the methods used in, or the facilities or controls used for, the manufacture, packing, storage, or installation of the device do not conform to the requirements of Section 520(f)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) or a condition prescribed by an order under section 520(f)(2) of the FD&C Act.
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 12/18/2025 | 81PCZINVESTIGATIONAL USE ONLY - IMMUNOLOGY | Division of Southeast Imports (DSEI) | |
| 12/18/2025 | 81PCZINVESTIGATIONAL USE ONLY - IMMUNOLOGY | Division of Southeast Imports (DSEI) | |
| 5/2/2025 | 79FMKSINGLE USE ONLY BLOOD LANCET WITH AN INTEGRAL SHARPS INJURY PREVENTION FEATURE | Division of Southeast Imports (DSEI) | |
| 5/2/2025 | 79FMKSINGLE USE ONLY BLOOD LANCET WITH AN INTEGRAL SHARPS INJURY PREVENTION FEATURE | Division of Southeast Imports (DSEI) | |
| 8/8/2024 | 75PDAINVESTIGATIONAL USE ONLY - CLINICAL CHEMISTRY | Division of West Coast Imports (DWCI) | |
| 5/17/2024 | 75NBWSYSTEM, TEST, BLOOD GLUCOSE, OVER THE COUNTER | Division of Southeast Imports (DSEI) | |
| 2/27/2019 | 81GJSTEST, TIME, PROTHROMBIN | Division of Southeast Imports (DSEI) | |
| 10/11/2018 | 75JJXSINGLE (SPECIFIED) ANALYTE CONTROLS (ASSAYED AND UNASSAYED) | Division of Southeast Imports (DSEI) | |
| 5/18/2018 | 62ZIP27OBINUTUZUMAB (ANTI-NEOPLASTIC - PART II) | Division of Northern Border Imports (DNBI) | |
| 3/14/2018 | 79FMKSINGLE USE ONLY BLOOD LANCET WITH AN INTEGRAL SHARPS INJURY PREVENTION FEATURE | Division of Southeast Imports (DSEI) | |
| 1/25/2016 | 75NBWSYSTEM, TEST, BLOOD GLUCOSE, OVER THE COUNTER | Cincinnati District Office (CIN-DO) | |
| 11/9/2015 | 75JILENZYMATIC METHOD, GLUCOSE (URINARY, NON-QUANT.) | 16DIRECTIONS | Division of Southeast Imports (DSEI) |
| 6/5/2014 | 62IIR99ANTI-NEOPLASTIC N.E.C. | Los Angeles District Office (LOS-DO) | |
| 6/5/2014 | 62IIR99ANTI-NEOPLASTIC N.E.C. | Los Angeles District Office (LOS-DO) | |
| 12/19/2011 | 62CCR99ANTI-HYPERTENSIVE N.E.C. | 118NOT LISTED | Atlanta District Office (ATL-DO) |
| 12/1/2011 | 75NBWSYSTEM, TEST, BLOOD GLUCOSE, OVER THE COUNTER | 2780DEVICEGMPS | New York District Office (NYK-DO) |
| 10/18/2011 | 75NBWSYSTEM, TEST, BLOOD GLUCOSE, OVER THE COUNTER | 333LACKS FIRM | New Orleans District Office (NOL-DO) |
| 1/4/2011 | 83JTODISCS, STRIPS AND REAGENTS, MICROORGANISM DIFFERENTIATION | 118NOT LISTED | New Orleans District Office (NOL-DO) |
| 8/28/2009 | 75JJWURINALYSIS CONTROLS (ASSAYED AND UNASSAYED) | New Orleans District Office (NOL-DO) | |
| 4/4/2008 | 88LDTREAGENT, GENERAL PURPOSE | Los Angeles District Office (LOS-DO) | |
| 12/14/2007 | 81GJSTEST, TIME, PROTHROMBIN | New Orleans District Office (NOL-DO) | |
| 9/8/2006 | 57DY20HUMAN SERUM | New York District Office (NYK-DO) | |
| 9/8/2006 | 57DY20HUMAN SERUM | New York District Office (NYK-DO) | |
| 7/28/2006 | 56KCS12CHLORAMPHENICOL SODIUM SUCCINATE | New York District Office (NYK-DO) | |
| 6/26/2006 | 63FCS06DIGOXIN (CARDIOTONIC) | 16DIRECTIONS | New York District Office (NYK-DO) |
| 4/22/2003 | 34CYY99CHOCOLATE AND CHOCOLATE COVERED CANDY, WITH NUTS OR NUT PRODUCTS, N.E.C. (NOT COCONUT) | 324NO ENGLISH | New Orleans District Office (NOL-DO) |
| 8/27/2002 | 83JXAKIT, SCREENING, URINE | Los Angeles District Office (LOS-DO) | |
| 11/26/2001 | 66VIP99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
Frequently Asked Questions
What is Roche Diagnostics GmbH's FDA import refusal history?
Roche Diagnostics GmbH (FEI: 3002806559) has 28 FDA import refusal record(s) in our database, spanning from 11/26/2001 to 12/18/2025.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Roche Diagnostics GmbH's FEI number is 3002806559.
What types of violations has Roche Diagnostics GmbH received?
Roche Diagnostics GmbH has been cited for 11 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about Roche Diagnostics GmbH come from?
All FDA import refusal data for Roche Diagnostics GmbH is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.